Harish Seethapathy

TL;DR: AKI is common in patients receiving checkpoint inhibitor therapy and merit thorough evaluation, and the role of PPI and other nephritis-inducing drugs in the development of sustained AKI needs to be better defined.

TL;DR: In this paper, a multivariable logistic regression model was used to identify predictors of ICPi-AKI and its recovery, and the effect of rechallenge versus no re-challenge on survival was estimated.

TL;DR: In this case series of patients with diffuse large B-cell lymphoma receiving CAR-T therapy, AKI and electrolyte abnormalities occurred commonly in the context of cytokine release syndrome.

TL;DR: This cohort provides further validation that other drugs associated with acute interstitial nephritis may be involved in the pathogenesis of ICI-related AKI, and may be less common when compared to other classes of ICIs.

TL;DR: Clinicians must exert caution when rechallenging patients with pre-existing renal disease with ICI therapy in the event of a prior AKI from ICI-related allergic interstitial nephritis, as those with baseline renal disease have less "renal reserve," and repeated AKI events may push a patient closer to end-stage renal disease.